The DOI matches its Crossref record.
Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications
Abstract
The long–term effect of interferon alfa (IFN–α) in Chinese patients with chronic hepatitis B infection is unknown. A total of 411 chronic hepatitis B patients (208 treated with IFN–α and 203 as control) were followed up for hepatitis B serology and the development of hepatoma and other cirrhosis–related complications. The hepatitis B e antigen (HBeAg) seroconversion rate in the IFN–α-treated group, though significantly greater at 6 and 24 months, was comparable with the control group on subsequent follow–up, irrespective of pretreatment alanine transaminase (ALT) levels. HBeAg seroreversion rate was higher in the IFN–α group compared with the control group (21.1% vs. 2.2%; P = .001). Loss of hepatitis B surface antigen (HBsAg) occurred in 2.4% of the IFN–α-treated patients and 0.49% of the control patients (P = NS). Around 90% of the anti–HBe-positive patients in both groups were still hepatitis B virus (HBV)–DNA-positive by polymerase chain reaction (PCR) assay. Two patients suffered from hepatic reactivation during the course of treatment. Nine (4.3%) patients in the IFN–α group and 2 (1.0%) in the control group developed complications of cirrhosis and hepatoma (P = .062). In Chinese HBsAg carriers, IFN–α was of no long–term benefit in inducing HBeAg seroconversion or in the prevention of hepatoma and other cirrhosis–related complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Metadata
- Authors
- Yuen, M.-F., Hui, C.-K., Cheng, C.-C., Wu, C.-H., Lai, Y.-P., & Lai, C.-L.
- Venue
- Hepatology
- Published
- 2001-07
- Volume
- 34
- Issue
- 1
- Pages
- 139-145
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2102245402
- Cited by
- 232
- References
- 0
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications. https://app.cochat.ai/papers/10.1053/jhep.2001.25273
- The paper
- Yuen, M.-F., Hui, C.-K., Cheng, C.-C., Wu, C.-H., Lai, Y.-P., & Lai, C.-L. (2001). Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications. Hepatology. https://doi.org/10.1053/jhep.2001.25273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.